News

Clarient said that the new test has been clinically validated to use in the sub-classification of patients with non-small cell lung cancer (NSCLC), which accounts for approximately 85%

The legislation, known as the Continuing Chemical Facilities Antiterrorism Security Act, was introduced today by Senator Susan Collins (R-ME), together with Senators Mark Pryor (D-AR), George Voinovich (R-OH),

The company expects to complete dosing in Q3, 2010, in preparation for filing a New Drug Application (NDA) with the FDA in Q4, 2010. In 2009, an open-label

The company informed that the packager is configured with an 18” x 24” seal system that utilises 25” pre-perforated centerfolded packaging material to create a bag around the

Fluidigm’s Access Array IFC, when used with an Illumina GA II sequencer, can capture up to 12kb of sequence data per sample, or 576kb per array. With upcoming

As per the agreement, the Hutchinson Center is expected to perform exploratory studies on Homspera, specifically focusing on the area of cancer immunotherapy. The Center expects to raise

YM BioSciences said that the US patent numbers 7,648,981 and 7,648,982 extend the life of YM’s AeroLEF patent estate in the US to 2024. The company has also

The company will move all syrup-based product manufacturing to this facility. The facility marks Elder’s entry into injectables manufacturing, especially anti-infective products like cephalosporins. The new plant involved

Reportedly, the next data analysis is anticipated to take place during Q2 2010. StemEx is being evaluated as a therapeutic treatment for adolescents and adults with blood cancers